We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in Connective Tissue Growth Factor (CTGF) and Hypoxia-Inducible Factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease, and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease.
Something looks off?